[ASH] A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 years

 关闭 求助已关闭
iefgnetuhz 发表于 2026-10-22 09:07:53 | 显示全部楼层 |阅读模式
悬赏10积分

期刊:Blood Journal

文献作者:Chong Chyn Chua; Wei-Hsun Hsun Hsu; Anoop K. Enjeti; Ashish Bajel; Paula Marlton; Shaun A Fleming; Devendra K. Hiwase; Chun-kei-kris Kris Ma; Peter J. Browett; Carolyn S. Grove; ShuhYing Tan; Travis Perera; Jad Othman; Hannah Rose; Julian P Cooney; Edward S Morris; Derek McCulloch; Kate Mason; Rachel M Koldej; Amanda Johnston; Stephen B Ting; David Ritchie; Natasha S Anstee; John Reynolds; Andrew H Wei

出版日期:--

DOI号:10.1182/blood.2026035389

下载链接:https://ashpublications.org/bloo ... lood.2026035389.pdf

文献链接:https://doi.org/10.1182/blood.2026035389

当前文献来源于 American Society of Hematology。


备注信息:
全部回复0 显示全部楼层

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

返回列表